Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

A new CDC vaccine panel, handpicked by RFK Jr., released an updated list of recommended vaccines. However, only if the ...

Health and Human Services Secretary Robert F. Kennedy Jr. Vaccine Advisers Sow Doubts as Scientists Protest U.S. Pivot on ...

The new members of the Advisory Committee on Immunization Practices began their tenure Wednesday by shifting the posture of ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...

MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.